A strain dormant for over a decade had caught global attention
Em meio a um surto de Ebola que já ceifou 131 vidas no leste da República Democrática do Congo, Washington escolheu o momento da crise para criticar publicamente a Organização Mundial da Saúde por sua resposta lenta — uma voz que ressoa com peso particular, pois os Estados Unidos se retiraram formalmente da OMS em janeiro de 2026. A cepa Bundibugyo, ausente por catorze anos, reapareceu na província de Ituri, lembrando ao mundo que as doenças não respeitam fronteiras políticas nem disputas institucionais. O episódio revela uma tensão mais profunda: no exato momento em que a coordenação global se torna mais necessária, as estruturas que a sustentam estão sendo contestadas.
- Uma cepa de Ebola dormente há 14 anos ressurge na província de Ituri, matando 131 pessoas e se espalhando em uma região já fragilizada por conflitos e infraestrutura precária.
- Washington aproveita a crise para atacar a OMS publicamente, citando o CDC americano como modelo de resposta mais ágil — uma crítica que ganha peso político com a retirada dos EUA da organização em janeiro de 2026.
- A OMS convoca um grupo técnico consultivo para definir estratégias de vacinação e terapias experimentais, tentando demonstrar capacidade de ação enquanto sua legitimidade é questionada.
- Um médico americano está entre os infectados, tornando o surto pessoalmente tangível para Washington mesmo após o rompimento formal com a entidade de saúde global.
- A ausência dos Estados Unidos — com seus recursos epidemiológicos e financeiros — levanta dúvidas sobre se parcerias alternativas conseguirão preencher o vazio deixado na resposta internacional.
Em maio de 2026, enquanto o Ebola avançava pelo leste da República Democrática do Congo, o Departamento de Estado americano acusou a Organização Mundial da Saúde de ter sido lenta demais para identificar a crise. O surto, causado pela cepa Bundibugyo — uma variante que não circulava há catorze anos —, já havia matado 131 pessoas na província de Ituri, próxima à fronteira com Uganda. Como contraponto, o governo americano destacou a mobilização mais rápida do CDC como prova de que outros atores poderiam agir com mais eficiência.
A OMS, por sua vez, já estava em movimento: avaliava vacinas candidatas e tratamentos existentes, e um grupo técnico consultivo foi convocado para o mesmo dia das críticas, com a missão de formular novas recomendações sobre imunização e terapias experimentais. O reaparecimento de uma cepa adormecida por mais de uma década adicionava urgência científica ao desafio logístico.
O momento da crítica americana carregava um peso simbólico inegável. Em janeiro de 2026, a administração Trump havia retirado os Estados Unidos da OMS, rompimento que refletia disputas mais amplas sobre governança global em saúde. Agora, Washington criticava de fora uma organização da qual não fazia mais parte — e da qual havia sido um dos maiores financiadores.
No terreno, além dos 131 mortos, um médico americano estava entre os infectados. A concentração dos casos em Ituri, província marcada por conflitos e infraestrutura limitada, tornava o controle ainda mais difícil. Enquanto o grupo técnico da OMS se reunia para traçar um caminho, fazia-o sem a participação formal dos Estados Unidos — e a pergunta que pairava era se parcerias alternativas seriam suficientes para compensar essa ausência enquanto o surto continuava a se expandir.
In May 2026, as an Ebola outbreak ravaged the eastern Democratic Republic of Congo, the U.S. State Department leveled a pointed criticism at the World Health Organization: it had been too slow to identify the crisis. The outbreak, linked to the Bundibugyo strain—a variant that had not circulated in fourteen years—had already claimed 131 lives, with new cases emerging across the region's Ituri province, near the border with Uganda. The American official cited the faster mobilization of the U.S. Centers for Disease Control as evidence that other actors could respond more effectively than the international body.
The WHO, for its part, was already in motion. The organization announced it was evaluating candidate vaccines and existing treatments to contain the epidemic. A technical advisory group was scheduled to convene the same day the criticism surfaced, tasked with formulating fresh recommendations on immunization strategies and experimental therapies. The outbreak's emergence of a strain dormant for over a decade had caught global attention, and the stakes were clear: the disease was spreading, and the tools to stop it—vaccines, treatments, coordination—remained in flux.
The timing of the American rebuke carried particular weight. In January 2026, the Trump administration had withdrawn the United States from the WHO entirely, a move that reflected broader tensions between the president and the international health organization. Those tensions had been building for months, rooted in disputes over global health governance rules and what the administration viewed as institutional failures. The withdrawal was not merely bureaucratic; it signaled a fundamental shift in how the United States would engage with multilateral health crises.
On the ground in Congo, the human toll was mounting. One American physician had contracted the virus, joining hundreds of infected patients across the affected region. The concentration of cases in Ituri, a province already strained by conflict and limited infrastructure, meant that containment efforts faced obstacles beyond the medical. The Bundibugyo strain itself presented a puzzle—its reemergence after so long dormant raised questions about its origin and transmission that epidemiologists were still working to answer.
The criticism from Washington underscored a deeper fracture in the international response to disease outbreaks. The WHO, despite its mandate to coordinate global health emergencies, now faced skepticism from one of its largest former contributors at a moment when coordination mattered most. The organization's technical advisory group would meet to chart a course forward, but it would do so without the formal participation of the United States—a country with substantial epidemiological expertise and resources. Whether the absence would hamper the response, or whether alternative channels and partnerships could fill the gap, remained an open question as the outbreak continued to spread.
Citações Notáveis
The U.S. State Department cited the faster mobilization of the CDC as evidence that other actors could respond more effectively than the WHO— U.S. State Department official
WHO announced it was evaluating candidate vaccines and existing treatments to contain the epidemic, with a technical advisory group scheduled to formulate fresh recommendations on immunization and experimental therapies— World Health Organization
A Conversa do Hearth Outra perspectiva sobre a história
Why did the State Department choose this moment to criticize the WHO's speed?
The outbreak was already at 131 deaths and spreading. When you're losing people that quickly, any delay in identification and response becomes a visible failure. The U.S. official was essentially saying: we could have acted faster.
But the WHO was already evaluating vaccines and treatments. Weren't they responding?
Yes, but there's a difference between identifying a problem exists and mobilizing a response. The criticism seems to be about the lag time between when cases first appeared and when the WHO formally recognized the scale of the crisis.
The Bundibugyo strain hadn't been seen in fourteen years. Doesn't that make it harder to spot?
It does. That's actually part of the puzzle. A strain that's been absent that long doesn't have recent surveillance infrastructure built around it. But that's also why early detection systems matter—and why the criticism stings.
How does the U.S. withdrawal from the WHO affect this outbreak response?
It removes a major player from the coordination table at a critical moment. The CDC can still work bilaterally with Congo and other partners, but you lose the unified command structure that the WHO is supposed to provide.
Is the American doctor's infection a sign the outbreak is spreading beyond the initial zone?
It suggests the virus is moving, or that healthcare workers are at high risk even in settings where Americans are present. Either way, it's a marker that the outbreak isn't contained to remote areas—it's touching people and places with international connections.
What happens at that technical advisory group meeting?
They'll decide which vaccines and experimental treatments to recommend, and how to prioritize them given limited supplies. Those decisions will shape what actually gets deployed in the coming weeks.